Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore which bond type—Treasury or corporate—typically incurs lower taxes in retirement and how that shapes your income strategy.
28,027 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
OpenAI reports Codex downloads exceed 1 million with over 1 million weekly active users, signaling a shift toward Cod...
Strategy’s stock soared february, jumping 35% from its February low and outpacing bitcoin’s gains as investors price ...
Investors often wonder if the memory chip darling Micron is still worth buying after a big run. This guide breaks dow...
A highly focused 3x Korea fund rides a memory-chip demand wave to striking gains, but risk factors and regulatory scr...
A coalition of over 200 crypto firms is pressing Congress for a floor vote on the CLARITY Act, warning that time is r...
June 2026 opens with a handful of beaten-down stocks that could roar back as inflation cools and earnings beat expect...
As AI reshapes the job market, a leading tech founder argues Gen Z should pursue two college majors to stay competiti...
A major investor moved a sizable stake in Hinge Health, triggering questions about timing and motives. This analysis ...
Air France will suspend flights to Havana for several weeks as Cuba faces a worsening fuel shortage and a weakened ec...
The question on many investors' minds is clear: is it too late to buy Ethereum in 2026? This article breaks down the ...
Bank of America initiates coverage on Salesforce with an Underperform rating and a $160 price target, highlighting un...